This article was originally published in The Gray Sheet
Executive SummaryFirst implant of the firm's Talent LoPro endoluminal stent graft system for minimally invasive repair of abdominal aortic aneurysm (AAA) is performed May 22 at the Montreal Heart Institute. The LoPro "features a 2 to 4 Fr lower profile introduction system compared to the original" Talent AAA system, U.S. clinical trials for which are scheduled for completion this fall. Arterial Vascular Engineering reported April 13 a stock-swap deal to purchase World Medical for $62 mil.; the deal is scheduled to close by July ("The Gray Sheet" April 20, p. 7)
You may also be interested in...
US investigators fan out to non-China inspection priorities and Secretary Azar talks supply management; warning letters hit record keeping, investigations and basic GMP compliance.
Mallinckrodt to pay $1.6bn and place its generics unit in bankruptcy under agreement in principle for US global settlement; six states are not on board, including New York, whose suit is still set to go to trial March 20.
The company has reached a broad opioid settlement agreement in principle under which its specialty generics subsidiaries would file for Chapter 11 bankruptcy and Mallinckrodt's branded business would operate separately.